Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Filippone et al. Inhibition of LRRK2 Attenuates Depression-Related Symptoms in Mice with Moderate Traumatic Brain Injury. <i>Cells</i> 2023, <i>12</i>, 1040.

Cells·2026

Same author

The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence.

Pharmacology research & perspectives·2026

Same author

Nrf2/NOX2 Pathway Dysregulation and Oxidative Stress Biomarkers in Gaucher Disease-Associated Parkinsonism: Insights Into a Potential Therapeutic Target.

Journal of cellular and molecular medicine·2026

Same author

Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors: Biology and Therapeutic Opportunities.

Oncology research·2026

Same author

RETRACTED: Scuderi et al. Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 2269.

International journal of molecular sciences·2026

Same author

Preconception body mass index and maternal thyroid function: a longitudinal observational study.

European thyroid journal·2026

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 30, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness.

Valentina Bova¹, Alessia Filippone¹, Giovanna Casili¹

¹Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy.

|August 26, 2022

Summary

This summary is machine-generated.

Extracellular adenosine protects glioblastoma by accumulating in the tumor microenvironment. Adenosine A2A receptor antagonists show promise in enhancing anti-cancer immunotherapy for brain tumors.

Keywords:

A2AAR antagonist adenosine adenosine receptors glioblastoma immune evasion tumor microenvironment

More Related Videos

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Aug 30, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Neuro-oncology
Immunology
Molecular Biology

Background:

Glioblastoma is an aggressive brain tumor with a high mortality rate.
Extracellular adenosine accumulates in the tumor microenvironment, acting as a tumor protector.
This accumulation is linked to A2A receptor interaction and increased CD39/CD73 expression under hypoxia.

Purpose of the Study:

To investigate the efficacy of adenosine receptor antagonists in glioblastoma treatment.
To explore the potential of these antagonists in enhancing anti-cancer immunotherapy.
To understand the role of adenosine pathway modulation in brain tumor therapy.

Main Methods:

Review of preclinical and clinical research on adenosine pathway modulators.
Focus on selective A2A receptor antagonists.
Analysis of adenosine's interaction with its receptor subtypes (A1, A2A, A2B, A3).

Main Results:

Extracellular adenosine accumulation promotes glioblastoma growth.
Selective A2A receptor antagonists competitively inhibit adenosine binding.
These antagonists are promising candidates for enhancing immunotherapy in brain tumors.

Conclusions:

Adenosine receptor antagonists represent a viable therapeutic strategy for glioblastoma.
Targeting the adenosine pathway can significantly enhance anti-cancer immunotherapy efficacy.
Further research into adenosine antagonists is crucial for brain tumor treatment.